These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 21668501)

  • 1. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
    Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Origa R; Karakas Z; Habr D; Zhu Z; Cappellini MD
    Eur J Haematol; 2014 Jun; 92(6):521-6. PubMed ID: 24460655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.
    Garbowski MW; Carpenter JP; Smith G; Roughton M; Alam MH; He T; Pennell DJ; Porter JB
    J Cardiovasc Magn Reson; 2014 Jun; 16(1):40. PubMed ID: 24915987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox: Over a Decade of Experience in Thalassemia.
    Moukalled NM; Bou-Fakhredin R; Taher AT
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018066. PubMed ID: 30416698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP; Keam SJ; Keating GM
    Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.
    Taher A; Elalfy MS; Al Zir K; Daar S; Al Jefri A; Habr D; Kriemler-Krahn U; Roubert B; El-Beshlawy A
    Eur J Haematol; 2011 Oct; 87(4):349-54. PubMed ID: 21668501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
    Porter J; Galanello R; Saglio G; Neufeld EJ; Vichinsky E; Cappellini MD; Olivieri N; Piga A; Cunningham MJ; Soulières D; Gattermann N; Tchernia G; Maertens J; Giardina P; Kwiatkowski J; Quarta G; Jeng M; Forni GL; Stadler M; Cario H; Debusscher L; Della Porta M; Cazzola M; Greenberg P; Alimena G; Rabault B; Gathmann I; Ford JM; Alberti D; Rose C
    Eur J Haematol; 2008 Feb; 80(2):168-76. PubMed ID: 18028431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
    Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
    Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia.
    Taher A; Elalfy MS; Al Zir K; Daar S; Al Jefri A; Habr D; Kriemler-Krahn U; El-Ali A; Roubert B; El-Beshlawy A
    Eur J Haematol; 2011 Oct; 87(4):355-65. PubMed ID: 21668502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
    Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron-chelating therapy and the treatment of thalassemia.
    Olivieri NF; Brittenham GM
    Blood; 1997 Feb; 89(3):739-61. PubMed ID: 9028304
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.